FDA head Makary defends drug application rejections amid criticism
Source: SeekingAlpha
2026-05-05 15:07:28 ET
More on Replimune
- Replimune: Second CRL May Have Sealed RP1's Fate - It's Hard To See Positives
- Replimune: Multiple Shots On Goal But A High Risk Binary Approaches
- RFK Jr. says no hand in rejecting Replimune’s lead asset
- Street sours on Replimune as stock hits all-time low on melanoma drug rejection
- Seeking Alpha’s Quant Rating on Replimune Group
Read the full article on Seeking Alpha
For further details see:
FDA head Makary defends drug application rejections amid criticism
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-2.99% G/L:
$5.035 Last:
1,693,266 Volume:
$5.06 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
